⌘K
Loading ticker…
As of 2026-08-24, Lyell Immunopharma, Inc. Common Stock (LYEL) has a 3-month relative strength percentile of 24 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 46. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.3%, relative volume 0.41×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
LYEL is held by 7 ETFs as of May 2026. Top owner: SCHA at 0.01% weight, $1M notional. Top 3 carry $2M.
Held by 15 ETFs · $18M across latest filings · largest weight 0.03% (IBBQ).
Top 7 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $1M | — |
| AVSC | 0.01% | $399K | — |
| VHTVanguard Health Care ETF | 0.00% | $397K | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $158K | — |
| IBBQ | 0.03% | $19K | — |
| BIB | 0.02% | $14K | — |
| AVUSAvantis U.S. Equity ETF | 0.00% | $6K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LYEL Jan avg: -10.31% median: -6.77% win: 0% σ: 7.87% n: 4 2022-04-12 → 2026-07-31 | LYEL Feb avg: 11.43% median: 10.21% win: 75% σ: 39.22% n: 4 2022-04-12 → 2026-07-31 | LYEL Mar avg: -13.65% median: -20.02% win: 25% σ: 16.01% n: 4 2022-04-12 → 2026-07-31 | LYEL Apr avg: -6.60% median: -3.02% win: 0% σ: 5.76% n: 5 2022-04-12 → 2026-07-31 | LYEL May avg: 9.05% median: -8.10% win: 40% σ: 32.43% n: 5 2022-04-12 → 2026-07-31 | LYEL Jun avg: -1.64% median: -0.31% win: 40% σ: 38.48% n: 5 2022-04-12 → 2026-07-31 | LYEL Jul avg: 2.61% median: -7.90% win: 40% σ: 19.84% n: 5 2022-04-12 → 2026-07-31 | LYEL Aug avg: -3.28% median: -8.06% win: 25% σ: 16.38% n: 4 2022-04-12 → 2026-07-31 (current) | LYEL Sep avg: 3.16% median: 2.29% win: 50% σ: 35.22% n: 4 2022-04-12 → 2026-07-31 | LYEL Oct avg: -8.76% median: -8.60% win: 50% σ: 19.79% n: 4 2022-04-12 → 2026-07-31 | LYEL Nov avg: 4.65% median: 1.47% win: 50% σ: 29.91% n: 4 2022-04-12 → 2026-07-31 | LYEL Dec avg: -2.37% median: -2.72% win: 50% σ: 27.53% n: 4 2022-04-12 → 2026-07-31 |